Transseksüalizm günümüzde geçmişe oranla toplumsal açıdan farkındalığın arttığı bir durumdur. Bu farkındalığın artışı ile karşı cins hormon tedavisi almak için başvuran trans birey sayısı dünyada ve ülkemizde her geçen gün artmaktadır. Bu sayının artmasının
kaçınılmaz bir sonucu olarak ; bu bireylerin hormon replasmanı ile izlemi ve bu süreçte meydana gelebilecek sorunlar tıp profesyonellerinin artık çok daha sık karşılaşacağı bir durum olacaktır. Bu sorunların tanınması ve yönetimi, cinsiyet değişim süreci konusunda klinisyen deneyimlerinin paylaşılması ile mümkün olacaktır.
Bu çalışma kliniğimizde takip edilen transseksüel bireylerin takip süreçlerindeki deneyimlerimizin sonuçlarını , uzun süreli karşı cins hormon tedavisi ile meydana gelen etki , yan etki, metabolik parametrelerdeki değişimleri ortaya koymayı ve bu sonuçları literatürdeki farklı ölçeklerde yapılmış çalışmalarla karşılaştırmayı amaçlamaktadır. Çalışmamızda trans kadın sayısının trans erkeklere oranla çok az olduğu görülmüştür. Trans erkeklerde hormon tedavisinin metabolik parametreler üzerine olan etkisine bakıldığında literatürdeki pek çok çalışma ile uyumlu olarak lipid panelinde anlamlı düzeyde bozulma ile uyumlu bulunmuştur. Takiplerden yola çıkarak ortaya konan bazı yan etkilerin ve metabolik parametrelerde
meydana gelen bozulmaların, hormonlarla ilişkisini daha iyi anlamak için daha uzun süreli ve standardize edilmiş takiplere ihtiyaç olduğu düşünülmüştür.
Bu çalışma ülkemizdeki trans bireylerin endokrinolojik değerlendirilmesini ele alan ve metabolik parametrelerin değişimini dökümante eden en geniş çaplı çalışma niteliğindedir.
59
7.KAYNAKÇA
1. Dhejne C, Van Vlerken R, Heylens G, Arcelus J. Mental health and gender dysphoria:
A review of the literature. International Review of Psychiatry. 2016.
2. American Psychological Association. Transgender people, gender identity and gender expression. Psychology Topics. 2017.
3. Öztürk O, Uluşahin A. Mental Health and Disorders [Ruh Sağlığı ve Bozuklukları]. Nobel Tıp Kitabevleri. 2018.
4. Sadock BJ, Sadock VA RP. Cinsiyetinde Hoşnutsuzluk. Çev. Bozkurt A. Kaplan&Sadock Psikiyatri Davranış Bilimler/Klinik Psikiyatri. 2016. 600–608 p.
5. Nguyen HB, Chavez AM, Lipner E, Hantsoo L, Kornfield SL, Davies RD, et al. Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition. Current Psychiatry Reports. 2018.
6. Coleman E. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People: An Introduction. In: Principles of Gender-Specific Medicine: Gender in the Genomic Era: Third Edition. 2017.
7. T’Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocrine Reviews. 2018.
8. Gooren L. The biology of human psychosexual differentiation. Horm Behav. 2006;
9. Hare L, Bernard P, Sánchez FJ, Baird PN, Vilain E, Kennedy T, et al. Androgen Receptor Repeat Length Polymorphism Associated with Male-to-Female Transsexualism. Biol Psychiatry. 2009;
10. Henningsson S, Westberg L, Nilsson S, Lundström B, Ekselius L, Bodlund O, et al. Sex steroid-related genes and male-to-female transsexualism. Psychoneuroendocrinology. 2005;
11. Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ, Poll N V.D., Koppe JG, Boer K. Prenatal exposure to anticonvulsants and psychosexual development. Arch Sex Behav. 1999;
12. Dessens AB, Slijper FME, Drop SLS. Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia. Archives of Sexual Behavior. 2005.
13. Berenbaum SA, Meyer-Bahlburg HFL. Gender development and sexuality in disorders of sex development. Hormone and Metabolic Research. 2015.
14. Meyer-Bahlburg HFL, Dolezal C, Baker SW, Ehrhardt AA, New MI. Gender development in women with congenital adrenal hyperplasia as a function of disorder severity. Arch Sex Behav. 2006; 15. Frisén L, Nordenström A, Falhammar H, Filipsson H, Holmdahl G, Janson PO, et al. Gender role
behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency. J Clin Endocrinol Metab. 2009;
16. Meyer-Bahlburg HFL, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI. Prenatal androgenization affects gender-related behavior but not gender identity in 5-12-year-old girls with congenital adrenal hyperplasia. Arch Sex Behav. 2004;
17. Heylens G, De Cuypere G, Zucker KJ, Schelfaut C, Elaut E, Vanden Bossche H, et al. Gender identity disorder in twins: A review of the case report literature. J Sex Med. 2012;
18. Fernández R, Esteva I, Gómez-Gil E, Rumbo T, Almaraz MC, Roda E, et al. Association study of ERβ, AR, and CYP19A1 genes and MtF transsexualism. J Sex Med. 2014;
60
disorder and sex hormone-related genes. Prog Neuro-Psychopharmacology Biol Psychiatry. 2009; 20. Lombardo F, Toselli L, Grassetti D, Paoli D, Masciandaro P, Valentini F, et al. Hormone and genetic
study inmale to female transsexual patients. J Endocrinol Invest. 2013;
21. Kreukels BPC, Guillamon A. Neuroimaging studies in people with gender incongruence. International Review of Psychiatry. 2016.
22. Rosenthal SM. Approach to the patient: Transgender youth: Endocrine considerations. Journal of Clinical Endocrinology and Metabolism. 2014.
23. Saraswat A, Weinand JD, Safer JD. Evidence supporting the biologic nature of gender identity. Endocrine Practice. 2015.
24. Steensma TD, Kreukels BPC, de Vries ALC, Cohen-Kettenis PT. Gender identity development in adolescence. Hormones and Behavior. 2013.
25. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/ gender-incongruent persons: An endocrine society∗clinical practice guideline. J Clin Endocrinol Metab. 2017;
26. E (Çev.:, Köroğlu) Hekimler Yayın Birliği A. Amerikan Psikiyatri Birliği (2013). Ruhsal Bozuklukların Tanısal ve Sayımsal El Kitabı, Beşinci Baskı (DSM-5), Tanı Ölçütleri Başvuru Elkitabı. 2013.
27. Dhejne C, Öberg K, Arver S, Landén M. An Analysis of All Applications for Sex Reassignment Surgery in Sweden, 1960–2010: Prevalence, Incidence, and Regrets. Arch Sex Behav. 2014;
28. WPATH. WPATH Standards of Care. Int J Tansgenderism. 2012;13(4):4.
29. Conron KJ, Scott G, Stowell GS, Landers SJ. Transgender health in massachusetts: Results from a household probability sample of adults. Am J Public Health. 2012;
30. Kuyper L, Wijsen C. Gender identities and gender dysphoria in the Netherlands. Arch Sex Behav. 2014; 31. Van Caenegem E, Wierckx K, Elaut E, Buysse A, Dewaele A, Van Nieuwerburgh F, et al. Prevalence of
Gender Nonconformity in Flanders, Belgium. Arch Sex Behav. 2015;
32. Oosterhuis H. Sexual modernity in the works of Richard von Krafft-Ebing and Albert Moll. Med Hist. 2012;
33. Bullough VL. Transsexualism in history. Arch Sex Behav. 1975;
34. Arcelus J, Bouman WP, Van Den Noortgate W, Claes L, Witcomb G, Fernandez-Aranda F. Systematic review and meta-analysis of prevalence studies in transsexualism. European Psychiatry. 2015.
35. Heylens G, Elaut E, Kreukels BPC, Paap MCS, Cerwenka S, Richter-Appelt H, et al. Psychiatric characteristics in transsexual individuals: Multicentre study in four European countries. British Journal of Psychiatry. 2014.
36. Auer M, Höhne N, Bazarra-Castro M, Pfister H, Fuss J, Stalla G, et al. Psychopathological profiles in transsexuals and the challenge of their special status among the sexes. Exp Clin Endocrinol Diabetes. 2013;
37. Bouman WP, Claes L, Brewin N, Crawford JR, Millet N, Fernandez-Aranda F, et al. Transgender and anxiety: A comparative study between transgender people and the general population. Int J
Transgenderism. 2017;
38. Marshall E, Claes L, Bouman WP, Witcomb GL, Arcelus J. Non-suicidal self-injury and suicidality in trans people: A systematic review of the literature. Int Rev Psychiatry. 2016;
39. Gómez-Gil E, Zubiaurre-Elorza L, Esteva I, Guillamon A, Godás T, Cruz Almaraz M, et al. Hormone- treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology. 2012;
61
40. Colizzi M, Costa R, Todarello O. Transsexual patients’ psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: Results from a longitudinal study.
Psychoneuroendocrinology. 2014;
41. Johansson A, Sundbom E, Höjerback T, Bodlund O. A five-year follow-up study of Swedish adults with gender identity disorder. Arch Sex Behav. 2010;
42. Heylens G, Verroken C, De Cock S, T’Sjoen G, De Cuypere G. Effects of Different Steps in Gender Reassignment Therapy on Psychopathology: A Prospective Study of Persons with a Gender Identity Disorder. J Sex Med. 2014;
43. Ruppin U, Pfäfflin F. Long-Term Follow-Up of Adults with Gender Identity Disorder. Arch Sex Behav. 2015;
44. Radix A. Hormone Therapy for Transgender Adults. Urologic Clinics of North America. 2019. 45. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone
therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2010.
46. Toorians AWFT, Thomassen MCLGD, Zweegman S, Magdeleyns EJP, Tans G, Gooren LJG, et al. Venous Thrombosis and Changes of Hemostatic Variables during Cross-Sex Hormone Treatment in Transsexual People. J Clin Endocrinol Metab. 2003;
47. Van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;
48. Center of Excellence for Transgender Health. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. Univ California, San Fr. 2016;
49. Gooren L. Hormone treatment of the adult transsexual patient. In: Hormone Research. 2005. 50. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones:
Extensive personal experience. J Clin Endocrinol Metab. 2008;
51. Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male- to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes. 2005;
52. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: A review of treatment regimens, outcomes, and adverse effects. Journal of Clinical Endocrinology and Metabolism. 2003. 53. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clinical Endocrinology. 2003. 54. Lapauw B, Taes Y, Simoens S, Van Caenegem E, Weyers S, Goemaere S, et al. Body composition,
volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008; 55. Ott J, Kaufmann U, Bentz EK, Huber JC, Tempfer CB. Incidence of thrombophilia and venous
thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;
56. Gooren LJG, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. Journal of Sexual Medicine. 2008.
57. Fernandez JD, Tannock LR. Metabolic effects of hormone therapy in transgender patients. Endocr Pract. 2016;
58. Asscheman H, Gooren LJG, Eklund PLE. Mortality and morbidity in transsexual patients with cross- gender hormone treatment. Metabolism. 1989;
59. Asscheman H, Giltay EJ, Megens JAJ, De Ronde W, Van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J
62
Endocrinol. 2011;
60. Maraka S, Ospina NS, Rodriguez-Gutierrez R, Davidge-Pitts CJ, Nippoldt TB, Prokop LJ, et al. Sex steroids and cardiovascular outcomes in transgender individuals: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;
61. Burke SM, Kreukels BPC, Cohen-Kettenis PT, Veltman DJ, Klink DT, Bakker J. Male-typical visuospatial functioning in gynephilic girls with gender dysphoria — Organizational and activational effects of testosterone. J Psychiatry Neurosci. 2016;
62. Sequeira GM, Miller E, McCauley H, Eckstrand K, Rofey D. Impact of Gender Expression on Disordered Eating, Body Dissatisfaction and BMI in a Cohort of Transgender Youth. J Adolesc Heal. 2017;
63. Mahfouda S, Moore JK, Siafarikas A, Hewitt T, Ganti U, Lin A, et al. Gender-affirming hormones and surgery in transgender children and adolescents. The Lancet Diabetes and Endocrinology. 2019. 64. SoRelle JA, Jiao R, Gao E, Veazey J, Frame I, Quinn AM, et al. Impact of hormone therapy on
laboratory values in transgender patients. Clin Chem. 2019;
65. Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: A systematic review and meta-analyses. Clinical Endocrinology. 2010. 66. Vita R, Settineri S, Liotta M, Benvenga S, Trimarchi F. Changes in hormonal and metabolic parameters
in transgender subjects on cross-sex hormone therapy: A cohort study. Maturitas. 2018;
67. Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol. 2009;
68. Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-Term Evaluation of Cross-Sex Hormone Treatment in Transsexual Persons. J Sex Med. 2012;
69. Mueller A, Zollver H, Kronawitter D, Oppelt PG, Claassen T, Hoffmann I, et al. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using
gonadotrophin-releasing hormone agonist. Exp Clin Endocrinol Diabetes. 2011;
70. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Translational Andrology and Urology. 2016.
71. Bui HN, Schagen SEE, Klink DT, Delemarre-Van De Waal HA, Blankenstein MA, Heijboer AC. Salivary testosterone in female-To-male transgender adolescents during treatment with intra-muscular injectable testosterone esters. Steroids. 2013;
72. Adeli K, Higgins V, Nieuwesteeg M, Raizman JE, Chen Y, Wong SL, et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: Establishment of robust pediatric and adult reference intervals on the basis of the Canadian health measures survey. Clin Chem. 2015;
73. Atsma F, Bartelink MLEL, Grobbee DE, Van Der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis. Menopause. 2006; 74. Muka T, Oliver-Williams C, Kunutsor S, Laven JSE, Fauser BCJM, Chowdhury R, et al. Association of
age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: A systematic review and meta-analysis. JAMA Cardiol. 2016;
75. Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. The Lancet Diabetes and
63
Endocrinology. 2016.
76. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse Events Associated with Testosterone Administration. N Engl J Med. 2010;
77. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non- fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014; 78. Wierckx K, Van de Peer F, Verhaeghe E, Dedecker D, Van Caenegem E, Toye K, et al. Short- and
Long-Term Clinical Skin Effects of Testosterone Treatment in Trans Men. J Sex Med. 2014; 79. Jockenhövel F. Testosterone therapy - What, when and to whom? In: Aging Male. 2004.
80. Futterweit W, Weiss RA, Fagerstrom RM. Endocrine evaluation of forty female-to-male transsexuals: Increased frequency of polycystic ovarian disease in female transsexualism. Arch Sex Behav. 1986; 81. Balen AH, Schachter ME, Montgomery D, Reid RW, Jacobs HS. Polycystic ovaries are a common
finding in untreated female to male transsexuals. Clin Endocrinol (Oxf). 1993;
82. H.A.G. B, M. P, G. B, R. A, M. H, W.G. S, et al. A higher rate of hyperandrogenic disorders in female- to-male transsexuals. Psychoneuroendocrinology. 1997;
83. Baba T, Endo T, Honnma H, Kitajima Y, Hayashi T, Ikeda H, et al. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod. 2007;
84. Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab. 2008; 85. Quirós C, Patrascioiu I, Mora M, Aranda GB, Hanzu FA, Gómez-Gil E, et al. Effect of cross-sex
hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia. Endocrinol y Nutr. 2015;
86. Elbers JMH, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf). 2003; 87. Richards C, Bouman WP, Seal L, Barker MJ, Nieder TO, Tsjoen G. Non-binary or genderqueer genders.